Vindesine effect in myeloid leukemia

descriptionPublicationkeyboard_double_arrow_right Article 01 Aug 1982 English Publisher:Springer Science and Business Media LLCJournal:Cancer Chemotherapy and Pharmacology, volume 8 (issn: 0344-5704, eissn: 1432-0843,

Copyright policy )

Authors: M, Baccarani; A, Zaccaria; G, Corbelli; S, Tura;

doi: 10.1007/bf00254046

pmid: 6957273

Vindesine effect in myeloid leukemia

- Summary
- Subjects
- Metrics

Abstract

Vindesine (VDS), a semisynthetic vinca alkaloid derivative, was given weekly at a dose of 3 mg/m2 as single-agent chemotherapy to seven patients with chronic myeloid leukemia (CML), 17 patients with chronic myeloid leukemia in blastic metamorphosis (CML/BM), and 12 patients with acute nonlymphocytic leukemia (ANLL). A substantial and rapid decrease of leukemic cells was obtained in 31 of 36 patients, and this was independent of cell phenotype and morphology. VDS may improve the results of polychemotherapy of ANLL, and is useful for palliative treatment of CML/BM.

Related Organizations

University of Trieste
Italy
Alma Mater Studiorum University of Bologna
Italy

Keywords

Blood, Vindesine, Leukemia, Myeloid, Humans, Antineoplastic Agents, Vinblastine

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	11
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average